In cell therapies, cryopreservation isn’t just about survival—it’s about preserving functional identity. Kryogene™ CFM-CGT delivers unmatched post-thaw potency by safeguarding immune cell markers critical for therapeutic efficacy.
Why Marker Integrity Matters
Immune cells lose functionality when surface markers (CD34+, CD56+, CAR expression) degrade during freezing. Kryogene™ solves this with:
l USP-compliant, serum-free formulation
l Ultra-low endotoxin (<0.5 EU/mL)
l Animal component-free chemistry
Reducing ice-crystal damage and oxidative stress to maintain cellular "memory."
Validated Performance Across Immune Cells
T Cells & CAR-Ts
l CAR expression retention: >98% post-thaw (vs. 85–92% in competitors)
l Cytokine secretion: IL-2/IFN-γ levels match fresh cells after activation
NK Cells
l CD56+/CD16+ purity: Maintained at 95% (Fig. 3)
l ADCC cytotoxicity: 80% tumor-killing efficiency vs. K562 targets
HSPCs (CD34+)
l Viability: >94% with intact CD34+/CD90+ populations
l Expansion capacity: 3,000–4,000x fold increase post-thaw (Fig. 1)
Beyond Markers: Functional Resilience
Kryogene™-cryopreserved cells don’t just look intact—they perform:
l Treg induction: Matches fresh-cell efficacy across donors
l DC maturation: 97% HLA-DR+/CD11c+ expression post-differentiation
l In vivo potency: 42.3% higher survival in septic mice vs. conventional solutions
Keywords:
#Cryopreservation #CellTherapy #Immunotherapy #Biomanufacturing #Kryogene #PotencyAssay #StemCells #BioTechInnovation